PUBLISHER: The Business Research Company | PRODUCT CODE: 1945351
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945351
An implantable glucose sensor is a small medical device placed beneath the skin to continuously measure the body's glucose levels and transmit the readings to an external monitor or smart device. It helps individuals manage diabetes more easily by offering real-time data without the need for frequent finger-prick tests. The device functions inside the body for an extended duration, providing a more convenient and consistent method for monitoring blood sugar.
The key product types of implantable glucose sensors include long-term implantable sensors and short-term implantable sensors. Long-term implantable sensors are glucose monitoring devices designed to remain under the skin for an extended period-typically weeks to months-to continuously measure blood glucose levels. These sensors utilize technologies such as enzymatic and non-enzymatic methods and are used for conditions such as type 1 diabetes, type 2 diabetes, and gestational diabetes. They serve end users including hospitals, clinics, home-care settings, and others.
Tariffs have moderately impacted the implantable glucose sensor market by increasing costs of semiconductor components, biocompatible materials, and sensor electronics sourced globally. Asia-Pacific manufacturing hubs and North American import-dependent suppliers are most affected, particularly long-term implantable sensor segments. These cost pressures have slightly slowed adoption in price-sensitive regions. However, tariffs are also encouraging localized manufacturing and innovation in cost-efficient sensor designs, supporting long-term market resilience.
The implantable glucose sensor market research report is one of a series of new reports from The Business Research Company that provides implantable glucose sensor market statistics, including implantable glucose sensor industry global market size, regional shares, competitors with a implantable glucose sensor market share, detailed implantable glucose sensor market segments, market trends and opportunities, and any further data you may need to thrive in the implantable glucose sensor industry. This implantable glucose sensor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The implantable glucose sensor market size has grown rapidly in recent years. It will grow from $8.14 billion in 2025 to $9.34 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to rising diabetes prevalence, limitations of finger stick testing, early adoption of CGM devices, increasing healthcare expenditure, improvements in sensor accuracy.
The implantable glucose sensor market size is expected to see rapid growth in the next few years. It will grow to $16.05 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to growing demand for long term monitoring, integration with insulin delivery systems, expanding diabetic population, technological miniaturization, supportive reimbursement policies. Major trends in the forecast period include long duration implantable monitoring, finger prick free diabetes management, improved biocompatible sensor materials, continuous real time glucose tracking, rising adoption of home based monitoring.
The rising prevalence of diabetes is expected to drive the growth of the implantable glucose sensor market in the coming years. Diabetes is a chronic condition in which the body cannot properly regulate blood sugar or glucose levels. Its prevalence is increasing largely due to unhealthy lifestyle habits, such as reduced physical activity and higher consumption of calorie-dense foods, which raise the risk of developing type 2 diabetes. Implantable glucose sensors support diabetes management by providing continuous, long-term monitoring of blood glucose levels, making them especially useful for patients who require tight glucose control. By offering real-time data and alerts, these devices reduce the need for frequent finger-prick tests, enhancing patient convenience and improving overall health outcomes. For example, according to the UK's National Health Service, in 2023, 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of diabetes is fueling the expansion of the implantable glucose sensor market.
Major players in the implantable glucose sensor market are focusing on developing advanced devices, such as long-term implantable sensors, to improve patient convenience, health outcomes, and reduce the need for frequent device management. Long-term implantable sensors are medical devices placed under the skin to continuously measure glucose levels in the interstitial fluid over extended periods, unlike short-term sensors that require frequent replacement. For instance, in September 2024, Senseonics Holdings Inc., a US-based medical technology company, received FDA approval for the Eversense 365 continuous glucose monitoring system for individuals aged 18 and older with Type 1 or Type 2 diabetes. The system features a fully implantable sensor that lasts up to 365 days, providing continuous glucose readings and alerts for high and low glucose levels. It also connects to a mobile app and cloud platform, allowing patients and healthcare providers to remotely monitor glucose trends and make informed treatment decisions.
In May 2024, Senseonics Holdings Inc. partnered with Mercy to expand the clinical adoption of the Eversense continuous glucose monitoring system across Mercy's network. This collaboration enables patients to benefit from long-duration implantable glucose monitoring, supported by remote patient monitoring and streamlined endocrinology workflows. Mercy is a US-based integrated healthcare organization offering hospital care, outpatient services, virtual care, and chronic disease management programs.
Major companies operating in the implantable glucose sensor market are Senseonics Holdings Inc., GlySens Incorporated, Profusa Inc., Abbott Laboratories, Dexcom Inc., Medtronic plc, Biolinq Inc., Nemaura Medical Inc., Integrated Sensing Systems Inc., WaveForm Technologies Inc., BioMems Solutions Inc., Echo Therapeutics Inc., Glucovation Inc., Know Labs Inc., Pacific Diabetes Technologies Inc., Metronom Health Inc., AliveCor Diabetes Inc., Pixelligent Technologies Inc., OrSense Ltd., Medtrum Technologies Inc.
North America was the largest region in the implantable glucose sensor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable glucose sensor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the implantable glucose sensor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The implantable glucose sensor market consists of sales of implantable glucose monitoring devices, biocompatible sensor probes, external data transmitters, wearable reader units, calibration accessories, and adhesive patches. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Implantable Glucose Sensor Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses implantable glucose sensor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for implantable glucose sensor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable glucose sensor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.